Closed Loop Medicine
Closed Loop Medicine (CLM) helps doctors and healthcare providers deliver personalised treatment regimens.
CLM is a new breed of therapeutics company that combines proven drug treatments with digital therapeutics. Digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease.
In May 2019, leading Cambridge angel investors including serial entrepreneur Sherry Coutu helped the health technology startup stride out of stealth via a £2.1 million pre-Series A round.
The venture capital funding was raised from Longwall Venture Partners, IQ Capital and Martlet, the investment arm of the Marshall of Cambridge group, and several Cambridge archangels. The funding round has enabled the company to take offices in London, invest in technical product development, start clinical development and clinical trials as well as invest further in drug development.
The CLM approach uses data and insights about how a patient is responding to treatment to tailor drug and non-drug therapy, which provides a much faster way of getting an individual to their optimum outcome.
The company intends to develop fully regulated, evidence-based Drug + Digital solutions for the NHS and international healthcare providers.
CLM was founded in 2017 and first secured seed funding from several angel investors via the Cambridge Angel network. In 2018 the company raised further funding from Longwall Venture Partners and Cambridge Angels.